DGKG

DGKG encodes diacylglycerol kinase gamma, a retina-enriched lipid kinase that functions in lipid signaling, neuronal development, and tumor biology through both kinase-dependent and kinase-independent mechanisms. In endothelial cells, DGKG is transcriptionally activated by HIF-1α under hypoxia and promotes tumor angiogenesis and immune evasion by recruiting USP16 to deubiquitinate and stabilize ZEB2, increasing TGF-β1 secretion that drives regulatory T-cell differentiation (PMID:37838036). In colorectal cancer cells, DGKG suppresses Rac1 activity, migration, and invasion through mechanisms that persist even with a kinase-dead mutant, indicating scaffolding or protein-interaction functions independent of its catalytic activity (PMID:28218473). In SST-expressing GABAergic interneurons, DGKG regulates neurite outgrowth, and a hypoxia-induced splice variant lacking exon 13 promotes glioblastoma proliferation and invasion more potently than the wild-type protein (PMID:29203264, PMID:40296900).

1. 1995 Medium

   Chromosomal mapping established the genomic identity and tissue-enrichment pattern of DGKG, placing it at 3q27-28 with predominant retinal expression, which focused subsequent functional studies on neural and vascular tissues.

   Evidence FISH mapping of human locus and interspecific backcross mapping of mouse homolog

   PMID:8585934

   Open questions at the time

   • No enzymatic characterization or substrate specificity analysis performed
   • Retinal function of DGKG not interrogated
2. 1999 Medium

   Full genomic characterization of DGKG (23 introns, >30 kb) and mutational screening in dominant optic atrophy patients excluded DGKG as the OPA1 disease gene, despite its retinal abundance.

   Evidence Genomic sequencing of intron-exon boundaries and mutation screening of 19 OPA1 patients

   PMID:10071200

   Open questions at the time

   • No retinal loss-of-function phenotype studied
   • Only one disease cohort tested
3. 2017 Medium

   Functional studies revealed that DGKG suppresses Rac1 activity, migration, and invasion in colorectal cancer cells, and crucially, kinase-dead mutants retained these inhibitory effects, establishing that DGKG possesses kinase-independent scaffolding or protein-interaction functions.

   Evidence Ectopic expression of wild-type, kinase-dead, and constitutively active mutants in CRC cell lines with Rac1 activity, migration, and invasion readouts

   PMID:28218473

   Open questions at the time

   • The kinase-independent binding partner mediating Rac1 suppression is unidentified
   • Findings limited to overexpression in CRC lines; endogenous loss-of-function not shown
4. 2017 Medium

   Loss-of-function analysis in primary ganglionic eminence neurons demonstrated that DGKG regulates neurite outgrowth specifically in SST-expressing GABAergic interneurons, establishing a neuronal developmental role.

   Evidence FACS-array screening for cell-type expression followed by knockdown in GE neurons with neurite outgrowth quantification

   PMID:29203264

   Open questions at the time

   • Downstream signaling pathway linking DGKG to neurite extension is undefined
   • In vivo interneuron phenotype not examined
5. 2023 High

   A comprehensive mechanistic study showed that endothelial DGKG, induced by HIF-1α under hypoxia, recruits USP16 to deubiquitinate ZEB2 (K48-linked), stabilizing it and increasing TGF-β1 secretion that drives tumor angiogenesis and regulatory T-cell differentiation — the first pathway-level mechanism for DGKG in the tumor microenvironment.

   Evidence Co-IP of USP16-DGKG-ZEB2 complex, HIF-1α promoter binding assay, knockdown/overexpression with in vivo HCC models, scRNA-seq, CyTOF, and flow cytometry

   PMID:37838036

   Open questions at the time

   • Whether the USP16-ZEB2 stabilization axis requires DGKG kinase activity is untested
   • Relevance beyond hepatocellular carcinoma endothelium not established
   • Structural basis for DGKG-USP16 interaction unknown
6. 2025 Medium

   A hypoxia-induced alternatively spliced DGKG isoform lacking exon 13 was identified as a more potent driver of glioblastoma proliferation and invasion than wild-type DGKG, with regulation of IL-16, CCN2, and EFNB3 expression, connecting hypoxia-responsive splicing to DGKG oncogenic gain-of-function.

   Evidence PCR-Sanger sequencing of splice variant, CCK-8 proliferation and Transwell invasion assays, orthotopic GBM mouse model, transcriptome analysis

   PMID:40296900

   Open questions at the time

   • Mechanism by which exon 13 loss enhances pro-tumorigenic activity is unclear
   • The splicing factor(s) responsible for the Δexon13 switch under hypoxia are not identified
   • Whether the Δexon13 isoform retains kinase activity is not determined

• Key unresolved questions include the structural basis for DGKG kinase-independent scaffolding functions, whether USP16 recruitment and Rac1 suppression share a common binding interface, the retinal function of DGKG, and how the Δexon13 splice variant gains enhanced oncogenic activity.
• No crystal or cryo-EM structure of DGKG exists
• Retinal loss-of-function phenotype has never been examined in vivo
• Relationship between kinase-independent Rac1 suppression and USP16/ZEB2 stabilization mechanisms is unexplored